These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Thomassen MJ; Meeker DP; Antal JM; Connors MJ; Wiedemann HP Am J Respir Cell Mol Biol; 1992 Sep; 7(3):257-60. PubMed ID: 1520490 [TBL] [Abstract][Full Text] [Related]
26. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Canadian Exosurf Neonatal Follow-Up Group. Casiro O; Bingham W; MacMurray B; Whitfield M; Saigal S; Vincer M; Long W J Pediatr; 1995 May; 126(5 Pt 2):S53-60. PubMed ID: 7745512 [TBL] [Abstract][Full Text] [Related]
27. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. Bhutani VK; Abbasi S; Long WA; Gerdes JS J Pediatr; 1992 Feb; 120(2 Pt 2):S18-24. PubMed ID: 1735846 [TBL] [Abstract][Full Text] [Related]
29. Elastase activity and surfactant protein concentration in tracheal aspirates from neonates receiving synthetic surfactant. Gerdes J; Whitsett J; Long W J Pediatr; 1992 Feb; 120(2 Pt 2):S34-9. PubMed ID: 1735850 [TBL] [Abstract][Full Text] [Related]
30. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. van Houten J; Long W; Mullett M; Finer N; Derleth D; McMurray B; Peliowski A; Walker D; Wold D; Sankaran K J Pediatr; 1992 Feb; 120(2 Pt 2):S40-4. PubMed ID: 1735851 [TBL] [Abstract][Full Text] [Related]
31. Distribution of surfactant, lung compliance, and aeration of preterm rabbit lungs after surfactant therapy and conventional and high-frequency oscillatory ventilation. Heldt GP; Merritt TA; Golembeski D; Gilliard N; Bloor C; Spragg R Pediatr Res; 1992 Mar; 31(3):270-5. PubMed ID: 1561014 [TBL] [Abstract][Full Text] [Related]
32. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593 [TBL] [Abstract][Full Text] [Related]
33. Prediction of the acute response to surfactant therapy by pulmonary function testing. Wallenbrock MA; Sekar KC; Toubas PL Pediatr Pulmonol; 1992 May; 13(1):11-5. PubMed ID: 1589306 [TBL] [Abstract][Full Text] [Related]
34. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: results of a double-blind trial. American Exosurf Neonatal Study Group I. Walther FJ; Mullett M; Schumacher R; Sundell H; Easa D; Long W J Pediatr; 1995 May; 126(5 Pt 2):S13-9. PubMed ID: 7745506 [TBL] [Abstract][Full Text] [Related]
35. Health and neurodevelopmental outcome at 1-year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactant. American Exosurf Neonatal Study Groups I and II. Gerdes J; Gerdes M; Beaumont E; Cook L; Dhanireddy R; Kopleman A; Jarret R; Long W J Pediatr; 1995 May; 126(5 Pt 2):S26-32. PubMed ID: 7745508 [TBL] [Abstract][Full Text] [Related]
37. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I. Sell M; Cotton R; Hirata T; Guthrie R; LeBlanc M; Mammel M; Long W J Pediatr; 1995 May; 126(5 Pt 2):S20-5. PubMed ID: 7745507 [TBL] [Abstract][Full Text] [Related]